ClinicalTrials.gg
CompletedNCT01029262MDS-005Updated Jun 25, 2019Results posted

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

A Phase 3 interventional study of Lenalidomide and Placebo in Anemia, sponsored by Celgene. Completed at 99 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Anemia by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 5 of them phase 3. Anemia · Bristol-Myers Squibb.

Enrollment
4th of 15
239 · median 189
Started
2010
with 1 other
Phase 3
7 of 16
none open now
Registered
2nd of 16
by date

Among the 16 studies in Anemia by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 2nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 16 studies in Anemia by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Anemia by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether lenalidomide would reduce the number of red blood cell transfusions (RBC) needed in anemic (RBC transfusion-dependent) participants with low or intermediate-1 risk MDS without a deletion 5q chromosome abnormality. The study also investigated the safety of lenalidomide use in these participants. Two-thirds of the participants received oral lenalidomide and one-third of the participants received oral placebo.

03

Conditions studied

  • Anemia

Keywords

  • Myelodysplastic Syndromes
  • MDS
  • transfusion dependent anemia
  • Erythropoiesis stimulating agents
  • non-del 5q
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Diagnosis of low or intermediate-1 risk Myelodysplastic (MDS) with any chromosome karyotype except del 5q[31]
  • Anemia that requires red blood cell transfusions
  • Resistant to erythropoiesis stimulating agents (ESAs) or blood erythropoietin level > 500 mU/mL
  • (ECOG) Performance Status (PS) ≤ 2
  • Must agree to follow pregnancy precautions as required by the protocol.
  • Must agree to receive counseling related to teratogenic and other risks of lenalidomide
  • Must agree not to donate blood or semen
  • Must be willing to consent to two or more bone marrow aspirate procedures to be completed during study

Exclusion criteria

Exclusion Criteria:

  • Subjects previously receiving immunomodulating or agents, or epigenetic or deoxyribonucleic acid (DNA) modulation agents
  • Allergic reaction to thalidomide
  • Renal insufficiency (CrC1)\<40 mL/min by Cockcroft-Gault method)
  • Prior history of cancer, other than MDS, unless the subject has been free of the disease for ≥ 5 years. (Basal cell carcinoma of the skin, carcinoma in situ of the cervix, or stage Tumor (T) 1a or T1b prostate cancer is allowed)
  • (ANC) \< 500/uL
  • \< 50,000/uL
  • (AST) or alanine aminotransferase (ALT) > 3X
  • Uncontrolled hyperthyroidism or hypothyroidism
  • Significant neuropathy
  • Prior stem cell transplantation
  • Anemia due to reasons other than MDS
  • History of deep venous thrombosis (DVT) or pulmonary embolus (PE) within past 3 years
  • Significant active cardiac disease within the past 6 months
  • Known (HIV) infection; known infection or active infection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Arm #1 - Lenalidomide plus placebo

    Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and \< 60 mL/min.

    Drug: Lenalidomide

  • Placebo comparator
    Arm #2 - placebo

    Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.

    Other: Placebo

Interventions

  • One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)

    Also known as: Revlimid, CC-5013

  • OtherPlacebo

    3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)

    The percentage of participants who achieved the 56-day RBC transfusion independent (TI) response was defined as the absence of any RBC transfusions during any consecutive "rolling" 56-day interval within the double-blind treatment phase (ie, Days 2 (Day 1 is the first study drug day) to 57, Days 3 to 58, etcetera). The double-blind treatment phase was defined as the period between the 1st dosing up until 28 days after the last study drug dose

    Time frame: From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

  2. Percentage of Participants With a Erythroid Gene Signature Who Achieved RBC Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)

    The percentage of participants who achieved the 56-day RBC TI response was defined as the absence of any RBC transfusions during any consecutive "rolling" 56-day interval within the double-blind treatment phase (ie, Days 2 (Day 1 is the first study drug day) to 57, Days 3 to 58, etcetera). A participant who achieved at least a 56-day RBC-transfusion-independent response was considered a 56-day RBC-TI responder.

    Time frame: From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

Secondary outcomes

  1. Percentage of Participants Who Achieved RBC Transfusion Independence With a Duration of ≥ 24 Weeks (168 Days) as Determined by the Sponsor

    The 168-day RBC-transfusion-independent response was defined as the absence of any RBC transfusion during any consecutive "rolling" 168 days during the treatment period, for example Days 2 (Day 1 is the first study drug day) to 169, Days 3 to 170, Days 4 to 171, etcetera. A responder was defined as a participant who had a ≥ 168 consecutive days of RBC-transfusion-free period after the first dose of study drug in the treatment phase.

    Time frame: From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

  2. Kaplan Meier Estimates of Duration of 56-day RBC Transfusion Independence Response as Determined by the Sponsor

    The duration of the first 56-day RBC transfusion-independence response was calculated for those who achieved a response and was dependent on whether a subsequent RBC transfusion was given after the transfusion-free period (response): * For those who received a subsequent RBC transfusion after the response starts, the duration of response was not censored, and was calculated as response duration = last day of response - first day of response +1 where the last day of response was defined as 1 day before the first RBC transfusion which was given at 56 days or more after the response starts. * For those who did not receive a subsequent RBC transfusion after the response started, the end day of the response was censored and duration of the response was calculated as response duration = date of last RBC transfusion assessment - first day of response+ 1. A responder was a participant who had a ≥ 56 consecutive days of RBC-transfusion-free period after the first study drug treatment period

    Time frame: Response was assessed up to the end of treatment; up to the data cut-off date of 17 Mar 2014.

  3. Percentage of Participants Who Achieved an Erythroid Response Based on the Modified International Working Group (IWG) 2006 Criteria

    A participant was considered as having achieved an erythroid response if the participant either: - had a hemoglobin (Hgb) increase ≥1.5 g/dL compared to baseline and confirmed by another central laboratory hemoglobin value at 4 to 8 weeks after the first Hgb measurement that also increased ≥1.5 g/dL. All Hgb values during this time interval must have had a ≥ 1.5 g/dL increase (ie, no central laboratory Hgb increase during this timeframe could be less \<1.5 g/dL) OR - had a 50% reduction in the number of the RBC transfusion units over any consecutive 56 days period compared to the baseline transfusion burden. The baseline transfusion burden is the number of units over 112 days by the randomization divided by 2. Only transfusions given for a pre-transfusion Hgb value of 9 g/dL or less were used in this response assessment.

    Time frame: From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

  4. Time to 56-Day RBC-Transfusion-Independent (TI) Response as Determined by the Sponsor

    The time to the first 56-day RBC-transfusion-independent response was calculated for participants who achieved a response. The day from the first dose of study drug to the date at which RBC-transfusion-independence starts was achieved and calculated using: Start date of the first response period - the date of the first study drug +1. A responder was defined as a participant who had a ≥ 56 consecutive days of RBC-transfusion-free period after the first dose of study drug in the treatment phase.

    Time frame: From first dose of study drug until 28 days after the last dose of study drug, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

  5. Kaplan Meier Estimates for Progression to Acute Myeloid Leukemia (AML)

    Progression to AML is part of the natural course of MDS and is a manifestation of disease progression. The time to progress to AML was calculated from the day of randomization to the first day when AML was diagnosed. Participants who died without AML were censored at the date of death. The participants who were lost to follow-up were censored at the last known day when participants did not have AML. Participants who did not progress to AML at the last follow-up contact were censored at the day of the last follow-up contact.

    Time frame: From randomization to final data cut-off date of 03 Jul 2018; median follow up time for progression to AML was 2.3 years (range = 0 to 5.0 years) in the placebo arm and 2.6 years (range = 0 to 6.4 years) in the lenalidomide arm.

  6. Kaplan Meier Estimate for Overall Survival (OS)

    Overall survival was assessed using the time between randomization and the date of death or date of censoring. Participants who were alive at a data cutoff date and participants who were lost to follow-up were censored at the last date when participants were known to be alive.

    Time frame: From randomization to final data cut-off date of 03 July 2018; maximum survival follow up was 6.4 years

  7. Number of Participants With Treatment Emergent Adverse Events (TEAE)

    A TEAE was defined as an AE that begins or worsens in intensity of frequency on or after the first dose of study drug through 28 days after last dose of study drug. A serious adverse event (SAE) is any: * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 3.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.

    Time frame: From the first dose of study drug through 28 days after discontinuation from the study treatment; up to the final data cut-off date of 03 July 2018; maximum exposure was 2100 days in the lenalidomide arm and 529 days in the placebo arm.

  8. Compliance Rates Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) From Baseline to Week 48

    The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. A participant was considered compliant at a visit if at least 15 out of the QLQ-C30 items in the questionnaire were checked.

    Time frame: Baseline, Week 12, (±3 days), Week 24, (±3 days), Week 36, (±3 days), and Week 48 (±3 days); up to data cut-off of 17 Mar 2014

  9. Mean Change From Baseline in the EORTC QLQ-C30 Fatigue Domain at Week 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Baseline and Week 12, ±3 days and Week 24, ±3 days

  10. Mean Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain at Week 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

    Time frame: Baseline and Week 12, ±3 days and Week 24, ±3 days

  11. Mean Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain at Week 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline and Week 12, ±3 days and Week 24, ±3 days

  12. Mean Change From Baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life (QOL) Domain at Week 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline and Week 12, ±3 days and Week 24, ±3 days

  13. Mean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain at Week 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Domain was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline and Week 12, ±3 days and Week 24, ±3 days

  14. Mean Change From Baseline in Fatigue Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

    The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  15. Mean Change From Baseline in the Dyspnea Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  16. Mean Change From Baseline in the Physical Functioning Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

    The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). The EORTC QLQ-C30 Physical Functioning was scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  17. Mean Change From Baseline in the Global Health Status/QoL Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

    The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  18. Mean Change From Baseline in the Emotional Functioning Domain Associated With the EORTC QLQ-C30 Scale at Weeks 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  19. Percentage of Participants With a Clinically Meaningful Improvement in QOL (EORTC QLQ-C-30 Scale) From Baseline in Fatigue Domain at Weeks 12 and 24

    The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. Improvement means at least 10 points better compared to baseline

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  20. Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Dyspnea Domain at Weeks 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom). Improvement means at least 10 points better compared to baseline.

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  21. Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline Within the Physical Functioning Domain at Weeks 12 and 24

    The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. A change of at least 10 points on the standardized domain scores was required for it to be considered clinically meaningful.

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  22. Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Global Health Status/QOL Domain at Weeks 12 and 24

    The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. A change of at least 10 points on the standardized domain scores was required for it to be considered clinically meaningful.

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  23. Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Emotional Functioning Domain at Weeks 12 and 24

    The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Domain was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

    Time frame: Baseline, Week 12, ±3 days and Week 24, ±3 days

  24. Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Related to Adverse Events Per Person Year

    Hospitalizations due to adverse events exclude those for transfusions, elective procedures or protocol-driven procedures. HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient.

    Time frame: From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

  25. Healthcare Resource Utilization (HRU): Duration of Hospitalizations Due to Adverse Events

    Hospitalizations due to adverse events exclude those for transfusions, elective procedures or protocol-driven procedures. HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient.

    Time frame: From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

  26. Healthcare Resource Utilization (HRU): Number of Days of Hospitalization Due to Adverse Events Per Person-Years

    Hospitalizations due to adverse events exclude those for transfusions, elective procedures or protocol-driven procedures. HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient

    Time frame: From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.

07

Results

Posted Jun 18, 2015

Participant flow

239 participants were randomized at sites located in Europe (185), North America (24), Asia/Pacific (13) and the Middle East (17).

Participant flow — Overall Study
MilestonePlaceboLenalidomide
Started79160
Completed00
Not completed79160
Withdrew: Adverse event952
Withdrew: Lack of therapeutic effect5776
Withdrew: Withdrawal by subject1017
Withdrew: Protocol violation23
Withdrew: Miscellaneous19
Withdrew: Death03

Outcome measures

PrimaryPercentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)

The percentage of participants who achieved the 56-day RBC transfusion independent (TI) response was defined as the absence of any RBC transfusions during any consecutive "rolling" 56-day interval within the double-blind treatment phase (ie, Days 2 (Day 1 is the first study drug day) to 57, Days 3 to 58, etcetera). The double-blind treatment phase was defined as the period between the 1st dosing up until 28 days after the last study drug dose

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)
percentage of participantsPlaceboLenalidomide
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)2.526.9
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = <0.001 · Risk ratio (rr): 10.616 · 95% CI 2.639 to 42.702p-value is from Fisher's exact test to compare lenalidomide treatment group to placebo group
PrimaryPercentage of Participants With a Erythroid Gene Signature Who Achieved RBC Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)

The percentage of participants who achieved the 56-day RBC TI response was defined as the absence of any RBC transfusions during any consecutive "rolling" 56-day interval within the double-blind treatment phase (ie, Days 2 (Day 1 is the first study drug day) to 57, Days 3 to 58, etcetera). A participant who achieved at least a 56-day RBC-transfusion-independent response was considered a 56-day RBC-TI responder.

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With a Erythroid Gene Signature Who Achieved RBC Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)
percentage of participantsPlaceboLenalidomide
Percentage of Participants With a Erythroid Gene Signature Who Achieved RBC Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)0.07.1
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 1.000p-value is from Fisher's exact test to compare lenalidomide treatment group to placebo group.
SecondaryPercentage of Participants Who Achieved RBC Transfusion Independence With a Duration of ≥ 24 Weeks (168 Days) as Determined by the Sponsor

The 168-day RBC-transfusion-independent response was defined as the absence of any RBC transfusion during any consecutive "rolling" 168 days during the treatment period, for example Days 2 (Day 1 is the first study drug day) to 169, Days 3 to 170, Days 4 to 171, etcetera. A responder was defined as a participant who had a ≥ 168 consecutive days of RBC-transfusion-free period after the first dose of study drug in the treatment phase.

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved RBC Transfusion Independence With a Duration of ≥ 24 Weeks (168 Days) as Determined by the Sponsor
percentage of participantsPlaceboLenalidomide
Percentage of Participants Who Achieved RBC Transfusion Independence With a Duration of ≥ 24 Weeks (168 Days) as Determined by the Sponsor0.017.5
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = < 0.001 (P-value is from Fisher's exact test to compare the lenalidomide arm to the placebo arm.) · Risk ratio (rr): 0
SecondaryKaplan Meier Estimates of Duration of 56-day RBC Transfusion Independence Response as Determined by the Sponsor

The duration of the first 56-day RBC transfusion-independence response was calculated for those who achieved a response and was dependent on whether a subsequent RBC transfusion was given after the transfusion-free period (response): * For those who received a subsequent RBC transfusion after the response starts, the duration of response was not censored, and was calculated as response duration = last day of response - first day of response +1 where the last day of response was defined as 1 day before the first RBC transfusion which was given at 56 days or more after the response starts. * For those who did not receive a subsequent RBC transfusion after the response started, the end day of the response was censored and duration of the response was calculated as response duration = date of last RBC transfusion assessment - first day of response+ 1. A responder was a participant who had a ≥ 56 consecutive days of RBC-transfusion-free period after the first study drug treatment period

Time frame:
Response was assessed up to the end of treatment; up to the data cut-off date of 17 Mar 2014.
Reported as:
Median · weeks
Kaplan Meier Estimates of Duration of 56-day RBC Transfusion Independence Response as Determined by the Sponsor
weeksPlaceboLenalidomide
Kaplan Meier Estimates of Duration of 56-day RBC Transfusion Independence Response as Determined by the SponsorNA (NA to NA)30.9 (20.7 to 59.1)
Statistical analysis
  • Placebo vs Lenalidomide · Log Rank · p = 0.639p-value from log-rank test to compare lenalidomide and placebo.
SecondaryPercentage of Participants Who Achieved an Erythroid Response Based on the Modified International Working Group (IWG) 2006 Criteria

A participant was considered as having achieved an erythroid response if the participant either: - had a hemoglobin (Hgb) increase ≥1.5 g/dL compared to baseline and confirmed by another central laboratory hemoglobin value at 4 to 8 weeks after the first Hgb measurement that also increased ≥1.5 g/dL. All Hgb values during this time interval must have had a ≥ 1.5 g/dL increase (ie, no central laboratory Hgb increase during this timeframe could be less \<1.5 g/dL) OR - had a 50% reduction in the number of the RBC transfusion units over any consecutive 56 days period compared to the baseline transfusion burden. The baseline transfusion burden is the number of units over 112 days by the randomization divided by 2. Only transfusions given for a pre-transfusion Hgb value of 9 g/dL or less were used in this response assessment.

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Erythroid Response Based on the Modified International Working Group (IWG) 2006 Criteria
percentage of participantsPlaceboLenalidomide
Percentage of Participants Who Achieved an Erythroid Response Based on the Modified International Working Group (IWG) 2006 Criteria30.438.8
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.252 (p-value is from Fisher's exact test to compare the lenalidomide arm to the placebo arm.) · Risk ratio (rr): 1.276 · 95% CI 0.867 to 1.877
SecondaryTime to 56-Day RBC-Transfusion-Independent (TI) Response as Determined by the Sponsor

The time to the first 56-day RBC-transfusion-independent response was calculated for participants who achieved a response. The day from the first dose of study drug to the date at which RBC-transfusion-independence starts was achieved and calculated using: Start date of the first response period - the date of the first study drug +1. A responder was defined as a participant who had a ≥ 56 consecutive days of RBC-transfusion-free period after the first dose of study drug in the treatment phase.

Time frame:
From first dose of study drug until 28 days after the last dose of study drug, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Median · weeks
Time to 56-Day RBC-Transfusion-Independent (TI) Response as Determined by the Sponsor
weeksPlaceboLenalidomide
Time to 56-Day RBC-Transfusion-Independent (TI) Response as Determined by the Sponsor0.3 (0.3 to 0.3)10.1 (0.3 to 23.6)
SecondaryKaplan Meier Estimates for Progression to Acute Myeloid Leukemia (AML)

Progression to AML is part of the natural course of MDS and is a manifestation of disease progression. The time to progress to AML was calculated from the day of randomization to the first day when AML was diagnosed. Participants who died without AML were censored at the date of death. The participants who were lost to follow-up were censored at the last known day when participants did not have AML. Participants who did not progress to AML at the last follow-up contact were censored at the day of the last follow-up contact.

Time frame:
From randomization to final data cut-off date of 03 Jul 2018; median follow up time for progression to AML was 2.3 years (range = 0 to 5.0 years) in the placebo arm and 2.6 years (range = 0 to 6.4 years) in the lenalidomide arm.
Reported as:
Median · years
Kaplan Meier Estimates for Progression to Acute Myeloid Leukemia (AML)
yearsPlaceboLenalidomide
Kaplan Meier Estimates for Progression to Acute Myeloid Leukemia (AML)NA (NA to NA)NA (5.2 to NA)
Statistical analysis
  • Placebo vs Lenalidomide · Log Rank · p = 0.864 (p-value from log-rank test to compare lenalidomide and placebo.)
SecondaryKaplan Meier Estimate for Overall Survival (OS)

Overall survival was assessed using the time between randomization and the date of death or date of censoring. Participants who were alive at a data cutoff date and participants who were lost to follow-up were censored at the last date when participants were known to be alive.

Time frame:
From randomization to final data cut-off date of 03 July 2018; maximum survival follow up was 6.4 years
Reported as:
Median · years
Kaplan Meier Estimate for Overall Survival (OS)
yearsPlaceboLenalidomide
Kaplan Meier Estimate for Overall Survival (OS)3.0 (2.3 to NA)3.8 (2.9 to 4.8)
Statistical analysis
  • Placebo vs Lenalidomide · Log Rank · p = 0.980 (p-value from log-rank test to compare lenalidomide and placebo.)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE)

A TEAE was defined as an AE that begins or worsens in intensity of frequency on or after the first dose of study drug through 28 days after last dose of study drug. A serious adverse event (SAE) is any: * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 3.0) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.

Time frame:
From the first dose of study drug through 28 days after discontinuation from the study treatment; up to the final data cut-off date of 03 July 2018; maximum exposure was 2100 days in the lenalidomide arm and 529 days in the placebo arm.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE)
ParticipantsPlaceboLenalidomide
At least 1 TEAE74160
≥ 1 Treatment Related AE (TEAE)42144
≥ 1 Treatment related TEAE Causing Discontinuation340
≥ 1 TEAE Leading to Dose Reduction110
≥ 1 TEAE Leading to Dose Interruption1189
≥ 1 TEAE Leading to Dose Interruption & Reduction568
≥ 1 TEAE Leading to Discontinuation of Study Drug951
≥ 1 Serious TEAE1662
≥1 Treatment-Related Serious TEAE325
≥1 Serious TEAE Leading to Dose Reduction01
≥1 serious TEAE leading to dose interruption421
≥1 SAE Causing Dose Interruption & reduction13
≥1 Serious TEAE Leading to Stopping of Study Drug424
≥1 Grade (GR) 3-4 TEAE35139
≥ 1 GR 3-4 Related TEAE16127
≥ 1 GR 3-4 Leading to Dose Reduction18
≥ 1 GR 3-4 TEAE Leading to Dose Interruption980
≥ 1 GR 3-4 TEAE dose Interruption &reduction464
≥ 1 GR 3-4 TEAE Leading to Stopping of Study Med641
≥ 1 GR 5 TEAE26
≥1 GR Treatment Related 5 TEAE13
SecondaryCompliance Rates Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) From Baseline to Week 48

The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. A participant was considered compliant at a visit if at least 15 out of the QLQ-C30 items in the questionnaire were checked.

Time frame:
Baseline, Week 12, (±3 days), Week 24, (±3 days), Week 36, (±3 days), and Week 48 (±3 days); up to data cut-off of 17 Mar 2014
Reported as:
Number · percentage of participants
Compliance Rates Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) From Baseline to Week 48
percentage of participantsPlaceboLenalidomide
Baseline88.690
Week 1278.583.8
Week 2480.685.8
Week 3610080.5
Week 485071.9
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.823The p-values are calculated based on the Fisher exact test
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.371The p-values are calculated based on the Fisher exact test
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.391The p-values are calculated based on the Fisher exact test
  • Placebo vs Lenalidomide · Fisher Exact · p = 1.000The p-values are calculated based on the Fisher exact test
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.508The p-values are calculated based on the Fisher exact test
SecondaryMean Change From Baseline in the EORTC QLQ-C30 Fatigue Domain at Week 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Baseline and Week 12, ±3 days and Week 24, ±3 days
Reported as:
Mean · units on a scale
Mean Change From Baseline in the EORTC QLQ-C30 Fatigue Domain at Week 12 and 24
units on a scalePlaceboLenalidomide
Week 120.6 ± 17.532.4 ± 28.26
Week 247.6 ± 20.74-1.5 ± 26.42
Statistical analysis
  • Placebo vs Lenalidomide · ANOVA · p = 0.323P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.
  • Placebo vs Lenalidomide · ANOVA · p = 0.071 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
SecondaryMean Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain at Week 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

Time frame:
Baseline and Week 12, ±3 days and Week 24, ±3 days
Reported as:
Mean · units on a scale
Mean Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain at Week 12 and 24
units on a scalePlaceboLenalidomide
Week 120.6 ± 28.062.2 ± 29.92
Week 244.3 ± 26.571.2 ± 26.26
Statistical analysis
  • Placebo vs Lenalidomide · ANOVA · p = 0.760 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score)
  • Placebo vs Lenalidomide · ANOVA · p = 0.251 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
SecondaryMean Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain at Week 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline and Week 12, ±3 days and Week 24, ±3 days
Reported as:
Mean · units on a scale
Mean Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain at Week 12 and 24
units on a scalePlaceboLenalidomide
Week 12-1.4 ± 15.76-2.1 ± 18.09
Week 24-5.7 ± 14.84-0.4 ± 18.19
Statistical analysis
  • Placebo vs Lenalidomide · ANOVA · p = 0.424 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
  • Placebo vs Lenalidomide · ANOVA · p = 0.116 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
SecondaryMean Change From Baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life (QOL) Domain at Week 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline and Week 12, ±3 days and Week 24, ±3 days
Reported as:
Mean · units on a scale
Mean Change From Baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life (QOL) Domain at Week 12 and 24
units on a scalePlaceboLenalidomide
Week 12-2.1 ± 20.18-1.4 ± 24.35
Week 24-4.1 ± 20.25-2.4 ± 27.87
Statistical analysis
  • Placebo vs Lenalidomide · ANOVA · p = 0.746 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
  • Placebo vs Lenalidomide · ANOVA · p = 0.460 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
SecondaryMean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain at Week 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Domain was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline and Week 12, ±3 days and Week 24, ±3 days
Reported as:
Mean · units on a scale
Mean Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain at Week 12 and 24
units on a scalePlaceboLenalidomide
Week 121.2 ± 18.70-1.4 ± 22.39
Week 24-7.1 ± 20.780.8 ± 20.06
Statistical analysis
  • Placebo vs Lenalidomide · ANOVA · p = 0.265 (P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
  • Placebo vs Lenalidomide · ANOVA · p = 0.047 (3\]: P-value from ANOVA comparison for change from baseline between lenalidomide and placebo adjusted with baseline score.)
SecondaryMean Change From Baseline in Fatigue Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom).

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Fatigue Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24
units on a scalePlaceboLenalidomide
Week 12-0.464 (-6.562 to 5.635)3.497 (-0.631 to 7.624)
Week 247.376 (0.990 to 13.762)0.196 (-4.505 to 4.897)
Statistical analysis
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.2909 (P-value is based on a two-sample t-test comparing the difference between treatments.)
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.0759 (P-value is based on a two-sample t-test comparing the difference between treatments.)
SecondaryMean Change From Baseline in the Dyspnea Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom).

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Dyspnea Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24
units on a scalePlaceboLenalidomide
Week 121.696 (-5.313 to 8.706)3.374 (-1.369 to 8.117)
Week 245.998 (-1.174 to 13.171)-0.206 (-5.557 to 5.146)
Statistical analysis
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.6957 (P-value is based on a two-sample t-test comparing the difference between treatments)
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.1729 (P-value is based on a two-sample t-test comparing the difference between treatments)
SecondaryMean Change From Baseline in the Physical Functioning Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). The EORTC QLQ-C30 Physical Functioning was scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Physical Functioning Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24
units on a scalePlaceboLenalidomide
Week 120.732 (-4.939 to 3.475)-2.919 (-5.768 to -0.071)
Week 24-5.451 (-10.046 to -0.85)-1.484 (-4.861 to 1.892)
Statistical analysis
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.3975P-value is based on a two-sample t-test comparing the difference between treatments.
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.1714 (P-value is based on a two-sample t-test comparing the difference between treatments.)
SecondaryMean Change From Baseline in the Global Health Status/QoL Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24

The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). The EORTC QLQ-C30 Global Health Status/QOL scale was scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in Global Health Status/QOL and positive values indicate improvement.

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Global Health Status/QoL Domain Associated With the EORTC QLQ-C-30 Scale at Week 12 and Week 24
units on a scalePlaceboLenalidomide
Week 12-1.201 (-6.401 to 3.999)-2.690 (-6.211 to 0.831)
Week 24-4.502 (-10.330 to 1.326)-2.441 (-6.761 to 1.880)
Statistical analysis
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.6408 (P-value is based on a two-sample t-test comparing the difference between treatments.)
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.5750 (P-value is based on a two-sample t-test comparing the difference between treatments.)
SecondaryMean Change From Baseline in the Emotional Functioning Domain Associated With the EORTC QLQ-C30 Scale at Weeks 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in the Emotional Functioning Domain Associated With the EORTC QLQ-C30 Scale at Weeks 12 and 24
units on a scalePlaceboLenalidomide
Week 121.458 (-3.621 to 6.536)-1.876 (-5.307 to 1.556)
Week 24-6.746 (-12.228 to -1.26)-1.129 (-5.174 to 2.917)
Statistical analysis
  • Placebo vs Lenalidomide · t-test, 2 sided · p = 0.2848P-value is based on a two-sample t-test comparing the difference between treatments
  • Placebo vs Lenalidomide · t-test, 1 sided · p = 0.1053 (P-value is based on a two-sample t-test comparing the difference between treatments)
SecondaryPercentage of Participants With a Clinically Meaningful Improvement in QOL (EORTC QLQ-C-30 Scale) From Baseline in Fatigue Domain at Weeks 12 and 24

The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. Improvement means at least 10 points better compared to baseline

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Meaningful Improvement in QOL (EORTC QLQ-C-30 Scale) From Baseline in Fatigue Domain at Weeks 12 and 24
percentage of participantsPlaceboLenalidomide
Week 1230.439.3
Week 2429.838.6
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.042 (The P-values are calculated based on Fisher exact test.)
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.448 (The P-values are calculated based on Fisher exact test.)
SecondaryPercentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Dyspnea Domain at Weeks 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Dyspnea scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate decreased dyspnea (i.e. improvement in symptom) and positive values indicate increased dyspnea (i.e. worsening of symptom). Improvement means at least 10 points better compared to baseline.

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Dyspnea Domain at Weeks 12 and 24
percentage of participantsPlaceboLenalidomide
Week 1219.621.3
Week 2412.820.5
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.825 (The P-values are calculated based on Fisher exact test.)
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.568 (The P-values are calculated based on Fisher exact test.)
SecondaryPercentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline Within the Physical Functioning Domain at Weeks 12 and 24

The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. A change of at least 10 points on the standardized domain scores was required for it to be considered clinically meaningful.

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline Within the Physical Functioning Domain at Weeks 12 and 24
percentage of participantsPlaceboLenalidomide
Week 1226.816.4
Week 2412.824.1
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.119 (The P-values are calculated based on Fisher exact test.)
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.172 (The P-values are calculated based on Fisher exact test.)
SecondaryPercentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Global Health Status/QOL Domain at Weeks 12 and 24

The European Organization for Research and Treatment of Cancer QOL Questionnaire for Patients with Cancer (EORTC QLQ-C30) was a 30-item oncology-specific questionnaire. The questionnaire was developed to assess the quality of life of cancer patients. It contains 30 questions, 24 of which form 9 multi-item scales representing various aspects of HRQOL: 1 global scale, 5 functional scales (Physical, Role, Emotional, Cognitive and Social), and 3 symptom scales (Fatigue, Pain, and Nausea). The remaining 6 items are intended to be mono-item scales describing relevant cancer-oriented symptoms (dyspnea, insomnia, appetite, constipation, diarrhea, financial difficulties). Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher score on symptom scales indicating worse symptoms. A change of at least 10 points on the standardized domain scores was required for it to be considered clinically meaningful.

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Global Health Status/QOL Domain at Weeks 12 and 24
percentage of participantsPlaceboLenalidomide
Week 1219.622.1
Week 2414.926.5
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.792 (The P-values were calculated based on Fisher exact test.)
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.279 (The P-values are calculated based on Fisher exact test.)
SecondaryPercentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Emotional Functioning Domain at Weeks 12 and 24

The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Domain was scored between 0 and 100, with a high score indicating better functioning. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement.

Time frame:
Baseline, Week 12, ±3 days and Week 24, ±3 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Meaningful Improvement in HRQOL Associated With the EORTC QLQ-C-30 Scale From Baseline in the Emotional Functioning Domain at Weeks 12 and 24
percentage of participantsPlaceboLenalidomide
Week 1225.020.5
Week 2417.021.7
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.476 (The P-values are calculated based on Fisher exact test.)
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.052 (The P-values are calculated based on Fisher exact test.)
Post-hocPercentage of Participants Who Achieved an Erythroid Response Based on Original IWG 2006 Criteria

A participant was considered as having achieved an erythroid response when: - a Hgb increase ≥1.5 g/dL compared to baseline and confirmed by another central laboratory hemoglobin value at 4 to 8 weeks after the first Hgb measurement that had also increased ≥1.5 g/dL for at least 8 weeks. All Hgb values during this time interval must have had a ≥ 1.5 g/dL increase (ie, no central laboratory Hgb increase during this timeframe can be less than a 1.5 g/dL) OR - had an absolute reduction of 4 RBC transfusion units over any consecutive 56 days period compared to the baseline transfusion burden. The baseline transfusion burden is the number of units over the 112 days prior to randomization divided by 2. Only transfusions given for a pre-transfusion Hgb value of 9.5 g/dL or less may be used in this response assessment.

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Erythroid Response Based on Original IWG 2006 Criteria
percentage of participantsPlaceboLenalidomide
Percentage of Participants Who Achieved an Erythroid Response Based on Original IWG 2006 Criteria20.335.6
Statistical analysis
  • Placebo vs Lenalidomide · Fisher Exact · p = 0.017 (p-value is from Fisher's exact test to compare lenalidomide treatment group to placebo group.) · Risk ratio (rr): 1.759 · 95% CI 1.083 to 2.856
SecondaryHealthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Related to Adverse Events Per Person Year

Hospitalizations due to adverse events exclude those for transfusions, elective procedures or protocol-driven procedures. HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient.

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Number · Hospitalizations per person-years
Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Related to Adverse Events Per Person Year
Hospitalizations per person-yearsPlaceboLenalidomide
Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Related to Adverse Events Per Person Year0.47 (0.3 to 0.75)0.77 (0.62 to 0.96)
SecondaryHealthcare Resource Utilization (HRU): Duration of Hospitalizations Due to Adverse Events

Hospitalizations due to adverse events exclude those for transfusions, elective procedures or protocol-driven procedures. HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient.

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Median · Days
Healthcare Resource Utilization (HRU): Duration of Hospitalizations Due to Adverse Events
DaysPlaceboLenalidomide
Healthcare Resource Utilization (HRU): Duration of Hospitalizations Due to Adverse Events9.0 (1.0 to 66.0)11.0 (1.0 to 76.0)
SecondaryHealthcare Resource Utilization (HRU): Number of Days of Hospitalization Due to Adverse Events Per Person-Years

Hospitalizations due to adverse events exclude those for transfusions, elective procedures or protocol-driven procedures. HRU was defined as any consumption of healthcare resources directly or indirectly related to the treatment of the patient

Time frame:
From first dose of study drug until 28 days after the last dose, as of the data cut-off date of 17 March 2014; median (minimum, maximum) duration of treatment was 168 (14, 449) and 164 (7, 1158) days in each treatment group respectively.
Reported as:
Number · Days per person-years
Healthcare Resource Utilization (HRU): Number of Days of Hospitalization Due to Adverse Events Per Person-Years
Days per person-yearsPlaceboLenalidomide
Healthcare Resource Utilization (HRU): Number of Days of Hospitalization Due to Adverse Events Per Person-Years6.37 (4.64 to 8.74)8.92 (7.35 to 10.82)

Adverse events

Collected over From the first dose of study drug through 28 days after last dose; up to the final data cut-off date of 03 July 2018; maximum exposure was 2100 days in the lenalidomide treatment group and 529 days in the placebo group. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo43/79 (54.4%)16/79 (20.3%)70/79 (88.6%)
Lenalidomide94/160 (58.8%)62/160 (38.8%)154/160 (96.3%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventPlaceboLenalidomide
PNEUMONIAInfections and infestations2/7910/160
ANAEMIABlood and lymphatic system disorders1/795/160
ATRIAL FIBRILLATIONCardiac disorders2/791/160
CARDIAC FAILURECardiac disorders2/793/160
BRONCHITISInfections and infestations2/790/160
ACUTE MYELOID LEUKAEMIANeoplasms benign, malignant and unspecified (incl cysts and polyps)2/790/160
NEUTROPENIABlood and lymphatic system disorders0/793/160
NEUTROPENIC SEPSISInfections and infestations0/793/160
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders0/793/160
DEEP VEIN THROMBOSISVascular disorders0/793/160
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPlaceboLenalidomide
NEUTROPENIABlood and lymphatic system disorders9/79102/160
DIARRHOEAGastrointestinal disorders18/7969/160
THROMBOCYTOPENIABlood and lymphatic system disorders6/7966/160
ASTHENIAGeneral disorders13/7938/160
CONSTIPATIONGastrointestinal disorders9/7936/160
FATIGUEGeneral disorders9/7936/160
OEDEMA PERIPHERALGeneral disorders14/7935/160
RASHSkin and subcutaneous tissue disorders4/7935/160
PRURITUSSkin and subcutaneous tissue disorders9/7930/160
NAUSEAGastrointestinal disorders12/7919/160

Baseline characteristics

The Intent-to-Treat (ITT) population includes all participants who were randomized.

Age, Continuous
Age, Continuous(years)PlaceboLenalidomideTotal
Mean68.9 ± 8.2670.0 ± 8.1969.6 ± 8.21
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLenalidomideTotal
Female255277
Male54108162
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboLenalidomideTotal
Asian112
Black or African American022
White69133202
Japanese4812
Race Not Disclosed41519
Other112
Packed RBC (pRBC) Transfusion Burden
Packed RBC (pRBC) Transfusion Burden(pRBC units/28 days)PlaceboLenalidomideTotal
Mean3.4 ± 1.373.4 ± 1.233.4 ± 1.28
International Prognostic Scoring System (IPSS) Investigator Determined
International Prognostic Scoring System (IPSS) Investigator Determined(Participants)PlaceboLenalidomideTotal
Low3085115
Intermediate 14975124
World Health Organization Classification 2008 of MDS by Central Review
World Health Organization Classification 2008 of MDS by Central Review(Participants)PlaceboLenalidomideTotal
Refractory anemia (RA)112
Refractory cytopenia unilineage dysplasia (RCUD)055
RA with ringed sideroblasts (RARS)71219
Refractory cytopenia multilineage dysplasia (RCMD)59115174
Refractory anemia with excess blasts-1 (RAEB-1)122739
Prior Erythropoiesis-stimulating Agent (ESA) Treatment
Prior Erythropoiesis-stimulating Agent (ESA) Treatment(Participants)PlaceboLenalidomideTotal
Yes63125188
No163551
Hemoglobin
Hemoglobin(g/dL)PlaceboLenalidomideTotal
Mean8.7 ± 1.378.7 ± 1.238.7 ± 1.28

1 further baseline measures are reported on the registry.

08

Study locations

99 sites
  • University of California at Los Angeles
    Los Angeles, California 90095, United States
  • Southern Illinois Hematology Oncology
    Centralia, Illinois 62801, United States
  • Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Wollongong Hospital
    Wollongong, New South Wales 2500, Australia
  • Royal Adelaide Hospital Institute of Medical and Veterinary Science
    Adelaide, South Australia 5000 SA, Australia
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
  • Medizinische Universitat Innsbruck
    Innsbruck, 6020, Austria
  • Krankenhaus der Elisabethinen Linz, I Interne Abteilung
    Linz, 4020, Austria
  • Universitatsklinik fur Innere Medizin Salzburg
    Salzburg, 5020, Austria
  • Klinikum Wels-Grieskirchen GmbH
    Weis, 4600, Austria
  • Wiener Gebietskrankenkasse-Hanusch-Krankenhaus
    Wien, 1140, Austria
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Centre Hospitalier Universitaire de Liege
    Liege, 4000, Belgium
  • Center Hospitalier Universitaire Ambroise Pare
    Mons, 7000, Belgium
  • Cliniques Universitaires UCL de Mont-Godine
    Namur, 5530, Belgium
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Cancer Care Manitoba
    Winnepeg, Manitoba R3E 0V9, Canada
  • Sunnybrook Regional Cancer Center
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Hospital and University of Toronto
    Toronto, Ontario M5G 2M9, Canada
  • Maisonneuve Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • McGill University, Dept. Oncology Clinical Research Program
    Montreal, Quebec H2W 1S6, Canada
  • Hopital du Sacre-Coeur de Montreal
    Montreal, Quebec H4J 1C5, Canada
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 77520, Czechia
  • Vseobecna Fakultni Nemocnice v Praze
    Prague, 12808, Czechia
  • Ustav hematologie a krevni transfuze
    Praha, 128 20, Czechia
  • CHU d'Angers
    Angers, 49033, France
  • Hopital Avicenne
    Bobigny Cedex, 93009, France
  • Hopital A. Michallon
    La Tronche, 38700, France
  • CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang
    Lille, 59037, France
  • Institut Paoli-Calmettes
    Marseille cedex, 13273, France
  • Groupe hospitalier Cochin Saint-Vincent de Paul
    Paris Cedex, 75679, France
  • BAG Freiberg-Richter, Jacobash, Illmer, Wolf
    Dresden, 1307, Germany
  • Marien Hospital
    Duesseldorf, 40479, Germany
  • Sankt Johannes Hospital Duisburg
    Duisberg, 47166, Germany
  • Universitätsklinikum Düsseldorf
    Düesseldorf, 40211, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Klinikum Mannheim der Universitat Heidelberg
    Heidelberg, 69120, Germany
  • Universitat zu Koln
    Köln, 50924, Germany
  • Universitatsklinikum Mannheim
    Mannheim, 68135, Germany
  • TU München - Klinikum rechts der Isar
    München, 81675, Germany
  • Rabin Medical Center
    Petach-Tikva, 49100, Israel
  • The Chaim Sheba Medical Center
    Tel Hashomer, 52621, Israel
  • Tel-Aviv Sourasky Medical Center
    Tel-Aviv, 64239, Israel
  • Az. Osp. SS.Antonio e Biagio - SC Ematologia
    Alessandria, 15100, Italy
  • A.O.U. di Bologna Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
  • P.O. Ospedale Roberto Binaghi (UNI CA/ASL 8)
    Cagliari, 09100, Italy
  • Azienda Ospedaliero-Universitaria di Cagliari
    Cagliari, 09121, Italy
  • Azienda Ospedaliero-Universitaria Careggi
    Firenze, 50139, Italy
  • Azienda Ospedaliera Cardarelli
    Naples, 80131, Italy
  • AOU San Luigi Gonzaga
    Orbassano, 10043, Italy
  • IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture
    Rionero in Vulture, Italy
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    Roma, 00133, Italy
  • Azienda Policlinico Umberto I, Universita La Sapienzadi Roma
    Roma, 00161, Italy
  • Policlinico Agostino Gemelli - Istituto di Ematologia
    Roma, 00168, Italy
  • Policlinico Univeristario di Udine
    Udine, 33100, Italy
  • Hiroshima University Hospital
    Hiroshima, Japan
  • Tokai University School of Medicine
    Isehara City, Kanagawa, 259-1193, Japan
  • Kameda General Hospital
    Kamogawa, 296-8602, Japan
  • Kanazawa University Hospital
    Kanazawa, Japan
  • Nagasaki Unversity Hospital
    Nagasaki, Japan
  • National Hospital Organization Nagoya Medical Center
    Nagoya, 460-0001, Japan
  • Osaka Red Cross Hospital
    Osaka, Japan
  • Tohoku University Hospital
    Sendai, 980-8574, Japan
  • Japanese Red Cross Medical Center
    Shibuya, 150-8935, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Japan
  • Kanto Medical Center NTT EC
    Shinagawa, Japan
  • Katedra i Klinika Hematologii i Transplantacji Szpiku - SLASKIEGO UNIWERSYTETU MEDYCZNEGO
    Gdansk, 80-119, Poland
  • Uniwersytet Medyczny w Lodzi
    Lodz, 93-510, Poland
  • Instytut Hematologii i Transfuzjologii, Klinika Hematologii
    Warsaw, 02-776, Poland
  • Hospitais da Universidade de Coimbra
    Coimbra, 3000-075, Portugal
  • Instituto Portugues de Oncologia de Lisboa
    Lisboa, 1090-023, Portugal
  • Hospital Geral de Santo Antonio
    Porto, 4099-001, Portugal
  • Hospital Clinic Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Virgen de la Victoria
    Malaga, 29010, Spain
  • Hospital Son Llatzer
    Palma de Mallorca, 7198, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • Hospital Universitario La Fe
    Valencia, 46009, Spain
  • Gazi Universitesi Tip Fakltesi
    Ankara, 06500, Turkey
  • Akdeniz Universitesi Tip Fakultesi
    Antalya, 07503, Turkey
  • Istanbul Universitesi Istanbul
    Istanbul, 34390, Turkey
  • Dokuz Eylul Universitesi Tip Faiultesi
    Izimir, 35340, Turkey
  • Royal Bournemouth Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XN, United Kingdom
  • Saint James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Barts Cancer Institute, Queen Mary University of London, Charterhouse Square
    London, EC1A 7BE, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Santini V, Almeida A, Giagounidis A, Gropper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del Canizo C, Gattermann N, Ozawa K, Risueno A, MacBeth KJ, Zhong J, Seguy F, Hoenekopp A, Beach CL, Fenaux P. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27. PubMed 27354480 ↗
  • Santini V, Almeida A, Giagounidis A, Skikne B, Beach CL, Weaver J, Tu N, Fenaux P. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leuk Lymphoma. 2020 Jun;61(6):1475-1483. doi: 10.1080/10428194.2020.1719088. Epub 2020 Feb 17. PubMed 32064987 ↗
  • Almeida A, Fenaux P, Garcia-Manero G, Goldberg SL, Gropper S, Jonasova A, Vey N, Castaneda C, Zhong J, Beach CL, Santini V. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leuk Lymphoma. 2018 Sep;59(9):2135-2143. doi: 10.1080/10428194.2017.1421758. Epub 2018 Jan 11. PubMed 29322849 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2010 to primary completion in Mar 2013, 37 months.

Results were first posted in Jun 2015, 2 years 3 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 37 months is above that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2009
First posted
Dec 9, 2009
StartActual
Jan 26, 2010
Primary completionActual
Mar 17, 2013
CompletionActual
May 9, 2018
Results first posted
Jun 18, 2015
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01029262
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Dec 9, 2009
Start date
Jan 26, 2010
Primary completion
Mar 17, 2013
Completion
May 9, 2018
Results posted
Jun 18, 2015
Last update
Jun 25, 2019

Study contacts

Albert Hoenekopp, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion